California biotech start-up shuts down commercial operations

The US biotech start-up Juno Diagnostics has announced it has ceased commercial operations, effective this week.

The company developing a range of DNA-based non-invasive prenatal screening tests has released a statement citing “unforeseen circumstances” that have led to what it described as a “difficult decision”.

“This decision comes with a heavy heart, as we so deeply understand the significance of the services we have provided to expectant mothers during the critical phase of pregnancy,” the company said.

“We recognise the trust you have placed in us and the pivotal role we played in offering accessible and innovative prenatal screenings.

“The journey to revolutionise prenatal care was one that we embarked upon with unwavering commitment and passion, guided by our mission to improve maternal and foetal health outcomes.

“Unfortunately, unforeseen circumstances have led to this difficult decision, and we’re devastated that we can no longer continue our mission-driven work to support expectant mothers like you.”

It added: “While our journey has ended, we remain hopeful that the advancements we introduced through our products will continue to pave the way for innovations in prenatal care.”

Since it was founded, Juno Diagnostics worked towards eliminating the need for traditional blood or venous draws to “shake up” the landscape of traditional prenatal care.